- Home
- CVKD vs ALBT Comparison
CVKD vs ALBT Comparison
Compare CVKD & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ALBT
- Stock Information
- Founded
- CVKD 2022
- ALBT 2014
- Country
- CVKD United States
- ALBT United States
- Employees
- CVKD N/A
- ALBT N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVKD Health Care
- ALBT Health Care
- Exchange
- CVKD Nasdaq
- ALBT Nasdaq
- Market Cap
- CVKD 29.5M
- ALBT 5.7M
- IPO Year
- CVKD 2023
- ALBT N/A
- Fundamental
- Price
- CVKD $12.71
- ALBT $2.57
- Analyst Decision
- CVKD Strong Buy
- ALBT
- Analyst Count
- CVKD 1
- ALBT 0
- Target Price
- CVKD $32.00
- ALBT N/A
- AVG Volume (30 Days)
- CVKD 35.8K
- ALBT 104.6K
- Earning Date
- CVKD 08-06-2025
- ALBT 08-18-2025
- Dividend Yield
- CVKD N/A
- ALBT N/A
- EPS Growth
- CVKD N/A
- ALBT N/A
- EPS
- CVKD N/A
- ALBT N/A
- Revenue
- CVKD N/A
- ALBT $807,235.00
- Revenue This Year
- CVKD N/A
- ALBT N/A
- Revenue Next Year
- CVKD N/A
- ALBT N/A
- P/E Ratio
- CVKD N/A
- ALBT N/A
- Revenue Growth
- CVKD N/A
- ALBT N/A
- 52 Week Low
- CVKD $5.70
- ALBT $2.11
- 52 Week High
- CVKD $22.90
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- CVKD 49.98
- ALBT 37.26
- Support Level
- CVKD $11.00
- ALBT $2.52
- Resistance Level
- CVKD $13.56
- ALBT $2.74
- Average True Range (ATR)
- CVKD 1.15
- ALBT 0.28
- MACD
- CVKD 0.25
- ALBT -0.01
- Stochastic Oscillator
- CVKD 80.97
- ALBT 5.15
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.